Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS).
暂无分享,去创建一个
B. Morland | S. Bielack | S. Strauss | F. Locatelli | A. Cañete | E. Thébaud | C. Rossig | M. Casanova | R. Venkatramani | Q. Campbell-Hewson | M. Gambart | I. Aerts | N. Gaspar | C. Dutcus | P. Marec-Berard | S. Hayato | C. He | F. Sirvent | S. Kraljevic | S. G. Melcon